BioSpace News Archive

An audio recording of the company’s shareholder update call, which was held on September 20, 2019, by PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, is now available for playback.

The real-time operating system for safety-critical applications is designed and developed to the highest achievable safety levels accepted by worldwide certification authorities, and now includes a full suite of safety certification evidence across sectors, including automotive, avionics, industrial, and medical.

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, announced today that the California Life Sciences Association (CLSA), the trade association representing California’s life sciences sector and its board of directors will honor Ionis with the 2019 Pantheon DiNA™ Award for Company of the Year.

Nucleus Biologics, a leader in precision cell culture, has announced the broader launch of Concierge™ Media Manufacturing Services.

Health Monitor Network (HM), a leading direct-to-patient/patient-engagement company, is named 2019 PM360 Trailblazer Award Company of the Year Gold Winner in the Supplier / Vendor (to the pharmaceutical marketing industry) category.

Check-Cap Ltd. (the “Company” or “Check-Cap”) (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), today announced the appointment of Dr. Vardit Segal as Vice President of Clinical Affairs, effective October 22, 2019.

Xstrahl Medical, global leader in superficial radiotherapy devices to treat non-melanoma skin cancer and dermatological conditions, is spotlighting its RADiant treatment system at the Fall American Osteopathic College of Dermatology (AOCD) meeting in Nashville, Tennesse from September 26th-28th.

Harvest’s Director of Community Outreach Marc Ross to Speak as Panelist Discussing “A Brand New Cannabis World”

LifeNet Health’s PliaFX®, its newest technology platform in osteobiologics, has received a 2019 Spine Technology Award from Orthopedics This Week, an exclusive recognition that highlights stand-out innovations in the field.

Initial phase 1 clinical data demonstrated that subcutaneous administration of RUC-4 resulted in a potent, rapid, and sustained platelet inhibition effect and was safe and well tolerated